


PRODUCT INFORMATION



SRI-37330

Item No. 31638

CAS Registry No.: 2322245-42-9
Formal Name: N-[[1-[6-(trifluoromethyl)-4-quinazolinyl]-3-piperidinyl]methyl]-methanesulfonamide
MF: C₁₆H₁₉F₃N₄O₂S
FW: 388.4
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SRI-37330 is supplied as a solid. A stock solution may be made by dissolving the SRI-37330 in the solvent of choice, which should be purged with an inert gas. SRI-37330 is soluble in acetonitrile.

SRI-37330 is sparingly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

SRI-37330 is an inhibitor of thioredoxin-interacting protein (TXNIP).¹ It inhibits the expression of *Txnip* mRNA in INS-1 rat insulinoma cells (IC₅₀ = 0.64 μM) and decreases Txnip protein levels in the same cells in a concentration-dependent manner. SRI-37330 (10 μM) inhibits LPS-induced pyroptosis in A549 cells overexpressing fat mass and obesity-associated (FTO) protein in an *in vitro* model of acute lung injury.² *In vivo*, SRI-37330 (100 mg/kg) reduces non-fasting and fasting blood glucose levels, serum glucagon levels, and hepatic glucose production in wild-type and *db/db* mice.¹ It also decreases non-fasting blood glucose levels, urinary glucose levels, and serum triglyceride levels in a mouse model of diabetes induced by streptozotocin (STZ; Item No. 13104).

References

1. Thielen, L.A., Chen, J., Jing, G., et al. Identification of an anti-diabetic, orally available small molecule that regulates TXNIP expression and glucagon action. *Cell Metab.* **32(3)**, 353-365.e8 (2020).
2. Xie, W.-M., Su, W., Liu, X.-Y., et al. FTO deficiency alleviate LPS-induced ALI by TXNIP/NLPR3-mediated alveolar epithelial cell pyroptosis. *Am. J. Respir. Cell Mol. Biol.* (2024).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/01/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM